KR890011823A - 벤조일 페닐아세트산 유도체 약제 조성물 - Google Patents

벤조일 페닐아세트산 유도체 약제 조성물 Download PDF

Info

Publication number
KR890011823A
KR890011823A KR1019890000892A KR890000892A KR890011823A KR 890011823 A KR890011823 A KR 890011823A KR 1019890000892 A KR1019890000892 A KR 1019890000892A KR 890000892 A KR890000892 A KR 890000892A KR 890011823 A KR890011823 A KR 890011823A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
salt
acid
composition according
sulfite
Prior art date
Application number
KR1019890000892A
Other languages
English (en)
Other versions
KR960005707B1 (ko
Inventor
다까히로 오가와
오시가즈 구리바야시
가즈미찌 우시오
아끼라 오오도리
Original Assignee
원본미기재
센쥬세이야꾸 가부시기가이샤
에이. 에이치. 로빈스 캄파니, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11923115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890011823(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 센쥬세이야꾸 가부시기가이샤, 에이. 에이치. 로빈스 캄파니, 인코오포레이티드 filed Critical 원본미기재
Publication of KR890011823A publication Critical patent/KR890011823A/ko
Application granted granted Critical
Publication of KR960005707B1 publication Critical patent/KR960005707B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

내용 없음

Description

벤조일 페닐아세트산 유도체 약제 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 아래 일반식의 벤조일페닐아세트산, 그염, 또는 산이나 염의 수화물을 유효성분으로 함유하는 염증질환 치료용 국소투여약제 조성물.
    위 식에서, R은 수소 또는 할로겐원자이다.
  2. 아래 일반식의 벤조일페닐아세트산, 그염 또는 산이나 염의 수화물을 유효성분으로 하고, 수용성폴리머 및 아황산염을 함유하며, pH를 약 6 내지 9로 조제한 염증질환치료용 국소투여약제 조성물.
    위 식에서, R은 수소 또는 할로겐원자이다.
  3. 제2항에 있어서, 수용성폴리머가 폴리비닐피롤리돈, 폴리비닐알콜, 카르복시프로필셀루로스, 히드록시 에틸셀루로스, 히드록시프로필셀루로스 또는 폴리아크릴산의 나트륨 염인 약제 조성물.
  4. 제2항에 있어서, 수용성 폴리머의 농도가 약 0.1 내지 1.0중량 %인 약제조성물.
  5. 제2항에 있어서, 아황산염이 나트륨, 칼륨, 칼슘 또는 마그네슘 염의 형태인 약제조성물.
  6. 제2항에 있어서, 아황산염의 농도가 0.1 내지 1중량 %인 약제조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890000892A 1988-01-27 1989-01-27 벤조일페닐아세트산 유도체 약제 조성물 KR960005707B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP88-16683 1988-01-27
JP63-16683 1988-01-27
JP1668388 1988-01-27

Publications (2)

Publication Number Publication Date
KR890011823A true KR890011823A (ko) 1989-08-22
KR960005707B1 KR960005707B1 (ko) 1996-05-01

Family

ID=11923115

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890000892A KR960005707B1 (ko) 1988-01-27 1989-01-27 벤조일페닐아세트산 유도체 약제 조성물

Country Status (12)

Country Link
US (1) US4910225A (ko)
EP (1) EP0326915B1 (ko)
JP (1) JP2683676B2 (ko)
KR (1) KR960005707B1 (ko)
AT (1) ATE80043T1 (ko)
AU (1) AU609932B2 (ko)
CA (1) CA1325382C (ko)
DE (1) DE68902649T2 (ko)
ES (1) ES2052784T3 (ko)
GR (1) GR3005586T3 (ko)
HK (1) HK162895A (ko)
PH (1) PH26827A (ko)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5895645A (en) * 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
DE19961307A1 (de) * 1999-12-18 2001-07-12 Krewel Meuselbach Gmbh Medizinprodukt zur Befeuchtung und Reinigung der Nasenschleimhaut
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
US6646003B2 (en) 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
JP2005525408A (ja) * 2002-05-03 2005-08-25 アルコン，インコーポレイテッド アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法
CN100341498C (zh) 2003-01-21 2007-10-10 千寿制药株式会社 含有2－氨基－3－(4－溴苯甲酰基)苯乙酸的水成液制剂
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
JP2007500250A (ja) * 2003-06-13 2007-01-11 アルコン，インコーポレイテッド 病的な眼の新脈管形成を処置するための非ステロイド性抗炎症剤の処方物
WO2005046700A1 (ja) * 2003-11-14 2005-05-26 Senju Pharmaceutical Co., Ltd. アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤
FR2876581B1 (fr) * 2004-10-20 2007-05-18 Interpharm Dev Composition bioadhesive a liberation programmee
KR20130080061A (ko) * 2004-11-05 2013-07-11 센주 세이야꾸 가부시키가이샤 안구 내 이행성 촉진 수성 점안제
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
PL1885336T3 (pl) * 2005-05-10 2009-08-31 Alcon Inc Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
CA2607014A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
EP1981491A4 (en) * 2006-01-25 2009-09-23 Aciex Inc COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DROUGHT
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
UY31058A1 (es) * 2007-05-01 2008-10-31 Alcon Res Ltd Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
EP2160182A1 (en) * 2007-05-24 2010-03-10 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
BRPI0908502A2 (pt) * 2008-02-21 2017-05-23 Ista Pharmaceuticals aines oftálmicos como adjuvantes
US8778999B2 (en) * 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2012099142A1 (ja) 2011-01-18 2012-07-26 千寿製薬株式会社 保存効力を有するブロムフェナク水性液剤組成物
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360040B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
MX358604B (es) 2012-11-19 2018-08-28 Bausch & Lomb Composicion liquida acuosa que contiene acido 2-amino-3-(4-bromobenzoil) fenilacetico.
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2016522257A (ja) 2013-06-19 2016-07-28 センティス リサーチ センター 安定なブロムフェナク溶液
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US20170000889A1 (en) 2013-12-12 2017-01-05 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN106404952B (zh) * 2016-08-31 2019-06-11 辰欣佛都药业（汶上）有限公司 一种溴芬酸钠滴眼液有关物质的测定方法
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2019117252A1 (ja) * 2017-12-14 2019-06-20 参天製薬株式会社 ２－アミノ－３－（４－ブロモベンゾイル）フェニル酢酸またはその塩を含有する点眼剤
CA3196559A1 (en) 2020-10-29 2022-05-05 Joon Youb Lee Ophthalmic composition
WO2022158893A2 (ko) 2021-01-21 2022-07-28 주식회사태준제약 점안 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU512570B2 (en) * 1975-08-13 1980-10-16 A.H. Robins Company, Incorporated Amino benzophenones
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
JPS58201710A (ja) * 1982-05-18 1983-11-24 Meiji Seika Kaisha Ltd 口腔内用抗炎症ペ−スト剤
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters

Also Published As

Publication number Publication date
CA1325382C (en) 1993-12-21
DE68902649D1 (de) 1992-10-08
US4910225A (en) 1990-03-20
GR3005586T3 (ko) 1993-06-07
DE68902649T2 (de) 1993-02-11
JPH02124817A (ja) 1990-05-14
ATE80043T1 (de) 1992-09-15
ES2052784T3 (es) 1994-07-16
AU609932B2 (en) 1991-05-09
AU2878689A (en) 1989-07-27
EP0326915A1 (en) 1989-08-09
JP2683676B2 (ja) 1997-12-03
HK162895A (en) 1995-10-27
PH26827A (en) 1992-11-05
EP0326915B1 (en) 1992-09-02
KR960005707B1 (ko) 1996-05-01

Similar Documents

Publication Publication Date Title
KR890011823A (ko) 벤조일 페닐아세트산 유도체 약제 조성물
KR900015722A (ko) N-(3,4-디메톡시신나모일) 안트라닐산을 함유하는 약제 조성물
US3510561A (en) Sulfone-enhanced heparin absorption through mucous membranes
RU94046143A (ru) Фармацевтическая композиция для лечения глаукомы
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR910000158A (ko) 의약용 화합물 및 그것의 사용방법
JPH0358935A (ja) ヒアルロン酸塩の安定な平衡塩媒体溶液
KR950703527A (ko) 프로스타글란딘 유도체
KR900001643A (ko) 항균제
RU99121654A (ru) Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
FI940224A0 (fi) Oksikamia tai oksikamijohdannaisia sisältävät oftalmiset koostumukset
KR920702226A (ko) 인체 면역 결핍 바이러스에 대한 항바이러스제
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
KR890003752A (ko) 2-피리미디닐-피페라딘 유도체의 용도
JP2634436B2 (ja) ラムサンガムを含有する局所用眼科用組成物
KR960704541A (ko) 유일한 치료제로서의 히드록실 이온 및 이 이온을 조정하는 화합물, 이 제제를 사용한 조성물, 이 제제를 사용하는 치료 방법 및 이의 제조 방법(Hydroxyl lons as Unique Therapeutic Agents and Compounds that Modulate These Ions, Compositions Employing These Agents, Therapeutic Methods for Using Such Agents and Processes for Preparing Them)
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR970706844A (ko) 트롬빈 억제제를 함유하는 저장 안정성 수용액상 주입액(A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor)
KR900701278A (ko) 바이러스 감염 치료용 담즙산
ES8203882A1 (es) Un procedimiento para la preparacion de 1-(8-quinole- il)-2-pirrolidinona y sus sales de adicion de acido
JPH0228573B2 (ko)
RU2073523C1 (ru) Препарат для лечения ожоговой болезни глаз i-iy степеней
EP1746082A1 (en) Salts of zinc and aliphatic haloid carboxylic acids for therapy of skin neoplasms and visible mucous coats
KR900013959A (ko) γ-카르블린 또는 그들의 제약학적으로 허용 가능한 산부가염 및/또는 수화물, 및 그들로 구성되는 제약학적 조성물
BR0200291A (pt) Composição farmacêutica lìquida para o uso no tratamento de doenças ósseas, processo para preparar a mesma e processo para tratamento de uma doença óssea

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100427

Year of fee payment: 15

EXPY Expiration of term